Skip to main
VALN
VALN logo

Valneva SE (VALN) Stock Forecast & Price Target

Valneva SE (VALN) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Valneva SE reported a 13% year-over-year increase in product sales for 2024, totaling €163.3 million, alongside a total revenue rise of 10% to €169.6 million compared to 2023. The company anticipates that Ixchiq sales will surpass €100 million by the third year of its commercial launch, driven by recent FDA accelerated approval and the anticipated expansion of the chikungunya vaccine market, projected to exceed $500 million annually. Furthermore, Valneva's management asserts the company has sufficient cash reserves to reach critical inflection points, reinforcing a strong financial outlook for future growth.

Bears say

Valneva SE faces a negative outlook primarily due to a substantial reduction in revenue estimates, with the 2025 projection decreased from €222.5 million to €185 million. Additionally, the expectation for 2025 earnings per share (EPS) has been downgraded to (€0.65) from (€0.53), indicating a worsening financial performance. The anticipated sales for the Ixchiq vaccine are also projected to decline significantly, with 2029 sales estimates being reduced to €225 million from €250 million, further compounding the challenges facing the company.

Valneva SE (VALN) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Valneva SE and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Valneva SE (VALN) Forecast

Analysts have given Valneva SE (VALN) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Valneva SE (VALN) has a Strong Buy consensus rating as of Aug 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Valneva SE (VALN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.